Top

European Journal of Medical Research

Published in:

Open Access 01-12-2023 | Cystectomy | Research

A model for predicting overall survival in bladder cancer patients with signet ring cell carcinoma: a population-based study

Authors: Liang Liu, Chuangui Li, Qiang Wang, Haibo Yuan, Yuanyuan Wang

Published in: European Journal of Medical Research | Issue 1/2023

Abstract

Introduction

This study is to examine the predictors of survival and to construct a nomogram for predicting the overall survival (OS) of primary bladder signet ring cell carcinoma (SRCC) patients based on the analysis of the Surveillance, Epidemiology, and End Results (SEER) database.

Methods

A total of 219 eligible patients diagnosed with SRCC were analyzed using the 2004–2015 data from SEER database. Univariate and multivariate Cox regression were used to determine independent prognostic factors, followed by development of a nomogram based on the multivariate Cox regression models. The consistency index (C-index), receiver operating characteristic (ROC) curve, and calibration curve were used to validate the prognostic nomogram.

Results

The nomograms indicated appreciable accuracy in predicting the OS, with C-index of 0.771 and 0.715, respectively. The area under the curve (AUC) of the nomogram was 0.713 for 1 year, 0.742 for 3 years, and 0.776 for 5 years in the training set, while was 0.730 for 1 year, 0.727 for 3 years, and 0.697 for 5 years in the validation set. The calibration curves revealed satisfactory consistency between the prediction of deviation correction and ideal reference line.

Conclusions

The prognostic nomogram developed in the analytical data of SEER it provided high accuracy and reliability in predicting the survival outcomes of primary bladder SRCC patients and could be used to comprehensively assess the risk of SRCC. Moreover, they could enable clinicians to make more precise treatment decisions for primary bladder SRCC patients.

https://gco.iarc.fr/today/online-analysis-table?v=2020&mode=cancer&mode_population=continents&population=900&populations=900&key=asr&sex=0&cancer=39&type=0&statistic=5&prevalence=0&population_group=0&ages_group%5B%5D=0&ages_group%5B%5D=17&group_cancer=1&include_nmsc=0&include_nmsc_other=1.

Grignon DJ, Ro JY, Ayala AG, Johnson DE. Primary signet-ring cell carcinoma of the urinary bladder. Am J Clin Pathol. 1991;95(1):13–20. https://doi.org/10.1093/ajcp/95.1.13.CrossRef

Akamatsu S, Takahashi A, Ito M, Ogura K. Primary signet-ring cell carcinoma of the urinary bladder. Urology. 2010;75(3):615–8. https://doi.org/10.1016/j.urology.2009.06.065.CrossRef

Lendorf ME, Dohn LHR, Dunga BÁ, Loya AC, Pappot H. An updated review on primary signet-ring cell carcinoma of the urinary bladder and report of a case. Scand J Urol. 2018;52(2):87–93. https://doi.org/10.1080/21681805.2017.1418020.CrossRef

Jin D, Qiu S, Jin K, Zhou X, Cao Q, Yang L, et al. Signet-ring cell carcinoma as an independent prognostic factor for patients with urinary bladder cancer: a population-based study. Front Oncol. 2020;10:653. https://doi.org/10.3389/fonc.2020.00653.CrossRef

Ferro M, Babă DF, de C O, et al. Neutrophil percentage-to-albumin ratio predicts mortality in bladder cancer patients treated with neoadjuvant chemotherapy followed by radical cystectomy. Future Sci OA. 2021;7(7):709. https://doi.org/10.2144/fsoa-2021-0008.CrossRef

Veskimäe E, Espinos EL, Bruins HM, Yuan Y, Sylvester R, Kamat AM, et al. What is the prognostic and clinical importance of urothelial and nonurothelial histological variants of bladder cancer in predicting oncological outcomes in patients with muscle-invasive and metastatic bladder cancer? a European association of urology muscle invasive and metastatic bladder cancer guidelines panel systematic review. Eur Urol Oncol. 2019;2(6):625–42. https://doi.org/10.1016/j.euo.2019.09.003.CrossRef

Humphrey PA, Moch H, Cubilla AL, Ulbright TM, Reuter VE. The 2016 WHO classification of tumours of the urinary system and male genital organs-part b: prostate and bladder tumours [J]. Eur Urol. 2016;70(1):106–19. https://doi.org/10.1016/j.eururo.2016.02.028.CrossRef

Holmäng S, Borghede G, Johansson SL. Primary signet ring cell carcinoma of the bladder: a report on 10 cases [J]. Scand J Urol Nephrol. 1997;31(2):145–8. https://doi.org/10.3109/00365599709070320.CrossRef

10.

Saphir O. Signet-ring cell carcinoma of the urinary bladder [J]. Am J Pathol. 1955;31(2):223–31.

11.

Allameh F, Fallah Karkan M, Nilipour Y, Rakhshan A. Primary signet-ring cell carcinoma of the urinary bladder successfully managed with radical cystectomy in a young patient. Case Rep Urol. 2017;2017:9121078. https://doi.org/10.1155/2017/9121078.CrossRef

12.

Bouhajja L, Farah F, Garbouj N, Rammeh S. Primary signet-ring cell carcinoma of the urinary bladder: a report of two cases. Tunis Med. 2019;97:167–9.

13.

Wang J, Wang FW. Clinical characteristics and outcomes of patients with primary signet-ring cell carcinoma of the urinary bladder. Urol Int. 2011;86:453–60. https://doi.org/10.1159/000324263.CrossRef

14.

Wang J, Wang FW, Kessinger A. The impact of signet-ring cell carcinoma histology on bladder cancer outcome. World J Urol. 2012;30:777–83. https://doi.org/10.1007/s00345-011-0718-8.CrossRef

15.

Dadhania V, Czerniak B, Guo CC. Adenocarcinoma of the urinary bladder [J]. Am J Clin Exp Urol. 2015;3(2):51–63.

16.

Ponz M, Luzuriaga J, Robles JE, Guillén F, Urmeneta JM, Salvá A, et al. Primary signet-ring cell carcinoma of the urinary bladder (linitis plastica) [J]. Eur Urol. 1985;11(3):212–4. https://doi.org/10.1159/000472497.CrossRef

17.

Choi H, Lamb S, Pintar K, Jacobs SC. Primary signet-ring cell carcinoma of the urinary bladder [J]. Cancer. 1984;53(9):1985–90. https://doi.org/10.1002/1097-0142(19840501)53:9%3c1985::aid-cncr2820530930%3e3.0.co;2-z.CrossRef

18.

Thomas AA, Stephenson AJ, Campbell SC, Jones JS, Hansel DE. Clinicopathologic features and utility of immunohistochemical markers in signet-ring cell adenocarcinoma of the bladder [J]. Hum Pathol. 2009;40(1):108–16. https://doi.org/10.1016/j.humpath.2008.06.022.CrossRef

19.

Romics I, Székely E, Szendroi A. Signet-ring cell carcinoma arising from the urinary bladder [J]. Can J Urol. 2008;15(5):4266–8.

20.

Burnett AL, Epstein JI, Marshall FF. Adenocarcinoma of urinary bladder: classification and management [J]. Urology. 1991;37(4):315–21. https://doi.org/10.1016/0090-4295(91)80256-7.CrossRef

21.

Guo L, Zhang L, Wang J, Zhang X, Zhu Z. Pelvic lymph node dissection during cystectomy for patients with bladder carcinoma with variant histology: does histologic type matter? Front Oncol. 2020;10:545921. https://doi.org/10.3389/fonc.2020.545921.CrossRef

22.

Pugashetti N, Yap SA, Lara PN, Gandour-Edwards R, Dall’Era MA. Metastatic signet-ring cell carcinoma of the urinary bladder: a novel management approach to a rare tumour [J]. Can Urol Assoc J. 2015;9(3–4):E204–7. https://doi.org/10.5489/cuaj.2447.CrossRef

23.

Hamakawa T, Kojima Y, Naiki T, Kubota Y, Yasui T, Tozawa K, et al. Long-term survival of a patient with invasive signet-ring cell carcinoma of the urinary bladder managed by combined s-1 and cisplatin adjuvant chemotherapy [J]. Case Rep Urol. 2013;2013:915874. https://doi.org/10.1155/2013/915874.CrossRef

24.

El Ammari JE, Ahsaini M, Riyach O, El Fassi MJ, Farih MH, Hammas N, et al. Primary signet-ring cell carcinoma of the urinary bladder successfully managed with cisplatin and gemcitabine: a case report. J Med Case Rep. 2013;7:37. https://doi.org/10.1186/1752-1947-7-37.CrossRef

25.

Schag CC, Heinrich RL, Ganz PA. Karnofsky performance status revisited: reliability, validity, and guidelines. J Clin Oncol. 1984;2(3):187–93. https://doi.org/10.1200/JCO.1984.2.3.187.CrossRef

26.

Iacovino ML, Miceli CC, De FM, et al. Novel therapeutic opportunities in neoadjuvant setting in urothelial cancers a new horizon opened by molecular classification and immune checkpoint inhibitors. Int J Mol Sci. 2022;23:3. https://doi.org/10.3390/ijms23031133.CrossRef

27.

Topalian SL, Drake CG, Pardoll DM. Immune checkpoint blockade: a common denominator approach to cancer therapy. Cancer Cell. 2015;27:450–61. https://doi.org/10.1016/j.ccell.2015.03.001.CrossRef

28.

Kamoun A, de Aure R, Allory Y, et al. A consensus molecular classification of muscle-invasive bladder cancer. Eur Urol. 2020;77(4):420–33. https://doi.org/10.1016/j.eururo.2019.09.006.CrossRef

29.

Rey-Cárdenas M, Guerrero-Ramos F, de Liaño G, Lista A, et al. Recent advances in neoadjuvant immunotherapy for urothelial bladder cancer: what to expect in the near future. Cancer Treat Rev. 2021;93:102142. https://doi.org/10.1016/j.ctrv.2020.102142.CrossRef

Title: A model for predicting overall survival in bladder cancer patients with signet ring cell carcinoma: a population-based study
Authors: Liang Liu
Chuangui Li
Qiang Wang
Haibo Yuan
Yuanyuan Wang
Publication date: 01-12-2023
Publisher: BioMed Central
Keyword: Cystectomy
Published in: European Journal of Medical Research / Issue 1/2023
Electronic ISSN: 2047-783X
DOI: https://doi.org/10.1186/s40001-022-00970-y

Keynote webinar | Spotlight on medication adherence

Springer Medicine

A model for predicting overall survival in bladder cancer patients with signet ring cell carcinoma: a population-based study

Abstract

Introduction

Methods

Results

Conclusions

Keynote webinar | Spotlight on medication adherence

Springer Medicine

Abstract

Introduction

Methods

Results

Conclusions

Please log in to get access to this content

Other articles of this Issue 1/2023

Differentiation between cerebral alveolar echinococcosis and brain metastases with radiomics combined machine learning approach

Identification and validation of core genes for type 2 diabetes mellitus by integrated analysis of single-cell and bulk RNA-sequencing

Clinical efficacy and complications of transurethral resection of the prostate versus plasmakinetic enucleation of the prostate

Diagnosis, pathophysiology and preventive strategies for cardiac surgery-associated acute kidney injury: a narrative review

Weekly versus triweekly cisplatin treatment in patients with locally advanced nasopharyngeal cancer during concurrent chemoradiotherapy

Correction: Protective effects of paraoxonase-1, vitamin E and selenium, and oxidative stress index on the susceptibility of low density lipoprotein to oxidation in diabetic patients with/without coronary artery disease